aibioLakewood-Amedex Biotherapeutics sets 1-for-10 reverse split, trading June 22, 2026
Tickers LABT
Outstanding shares will fall from about 17,506,577 to about 1,750,789. The stock stays on the Nasdaq Capital Market as LABT.
Key facts
- Company
- Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT)
- News type
- Listings
- Primary source
- Lakewood-Amedex Biotherapeutics Inc. 8-K (2026-06-17)
Lakewood-Amedex Biotherapeutics Inc. (Nasdaq: LABT) said in an 8-K filed June 17, 2026 that it filed a Certificate of Change with the Nevada Secretary of State on June 15, 2026 to effect a 1-for-10 reverse stock split. The split covers its issued and outstanding and authorized shares of common stock. The board approved it unanimously on June 1, 2026.
The split becomes effective at 4:01 p.m. Eastern Time on June 19, 2026. The common stock will begin trading on a split-adjusted basis when Nasdaq opens on June 22, 2026. It will continue to trade on The Nasdaq Capital Market under the symbol LABT, with a new CUSIP number, 51255A201.
Every ten shares will be exchanged for one share, and fractional shares will be rounded up to the next higher whole share. Issued and outstanding shares will fall from approximately 17,506,577 to approximately 1,750,789. Authorized common stock will be reduced proportionately to 12,500,000 shares.
Equitable adjustments will be made to shares issuable on exercise or conversion of equity awards, preferred stock and warrants, and to the related conversion and exercise prices.